On March 20, 2023 Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, reported the publication of abstracts for five posters that will be presented during the upcoming 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (AACR 2023), taking place from April 14th to 19th at the Orange County Convention Center in Orlando, Florida, the United States (Press release, Antengene, MAR 20, 2023, View Source [SID1234629062]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are honored to have the opportunity to present the latest results from our in-house discovery and clinical programs at AACR (Free AACR Whitepaper) 2023. This year, we have five abstracts selected for presentations at the AACR (Free AACR Whitepaper) Annual Meeting. These results underscore our focus on the tumor microenvironment and the unique role that immunology plays in cancer, including our expertise in discovering and developing small molecule and unique antibody drugs," said Dr. Bo Shan, Antengene’s Chief Scientific Officer. "Building these progress, we will continue to accelerate our preclinical and clinical programs in efforts to bring more innovative treatment options to patients as soon as possible."

Details of the posters and corresponding abstracts are shown below:

ATG-008 (mTORC1/2 inhibitor)

Title: Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib(ATG-008) in HBV+ advanced hepatocelllular carcinoma(HCC) subjects who have received at least one prior line of systemic therapy(TORCH)

Abstract: CT150

Session: Phase II Clinical Trials 1

Date: April 17, 2023

Time: 1:30 PM – 5:00 PM (Eastern Time)

1:30 AM – 5:00 AM, April 18, 2023 (Beijing Time)

Location: Poster Section 47

ATG-031 (anti-CD24 monoclonal antibody)

Title: ATG-031, a first-in-class humanized anti-CD24 antibody, demonstrates potent in vivo efficacy and repolarizes tumor-associated macrophages in the TME

Abstract: 6641

Session: Immune Checkpoints

Date: April 19, 2023

Time: 9:00 AM – 12:30 PM (Eastern Time)

9:00 PM April 19 – 12:30 AM April 20, 2023 (Beijing Time)

Location: Poster Section 38

ATG-037 (small molecule CD73 inhibitor)

Title: Targeting CD73-Adenosine Axis for the treatment of multiple myeloma

Abstract: 496

Session: Novel Antitumor Agents 1

Date: April 16, 2023

Time: 1:30 PM – 5:00 PM (Eastern Time)

1:30 AM – 5:00 AM, April 17, 2023 (Beijing Time)

Location: Poster Section 17

ATG-017 (ERK1/2 inhibitor)

Title: Synergistic effects of the combination of ERK1/2 with EGFR, KRASG12C, CDK4/6, and PD-L1 inhibition for cancer treatment

Abstract: 5499

Session: Combination Therapies for Cancer

Date: April 18, 2023

Time: 1:30 PM – 5:00 PM (Eastern Time)

1:30 AM – 5:00 AM, April 19, 2023 (Beijing Time)

Location: Poster Section 38

ATG-034 (LILRB4 antagonist antibody)

Title: ATG-034, an LILRB4 antagonist antibody, reinvigorates dendritic cells and prevents tumor progression

Abstract: 6384

Session: Immune Checkpoints

Date: April 19, 2023

Time: 9:00 AM – 12:30 PM (Eastern Time)

9:00 PM April 19 – 12:30 AM April 20, 2023 (Beijing Time)

Location: Poster Section 23